GlassScriptPhysician profile
Samantha E Davis
NPI 1346361599
$4,644.33
in general payments reported to CMS, 2019-2025
39 companies · $832 in 2025
The $832 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $1,445 · 2023: $1,212 · 2024: $1,016 · 2025: $832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,060.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,127.71 | 2021-2025 | |
| Eko Health, INC. | $600.00 | 2022 | |
| Abbott Laboratories | $404.92 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $356.59 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $334.01 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $222.33 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $159.75 | 2024-2025 | Rexulti |
| Amgen INC. | $147.21 | 2022-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $134.00 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.85 | 2022-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $125.57 | 2022 | |
| Pfizer INC. | $113.10 | 2023-2024 | |
| Novo Nordisk INC | $99.01 | 2022-2025 | Wegovy, Saxenda |
| Novartis Pharmaceuticals Corporation | $66.21 | 2024-2025 | |
| Antares Pharma, INC. | $49.77 | 2025 | Xyosted |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $49.10 | 2023-2024 | Azstarys |
| Viatris Specialty LLC | $46.86 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $44.07 | 2022-2023 | Gardasil 9, Vaxelis, Pneumovax 23 |
| Nestle Healthcare Nutrition INC. | $37.55 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $35.05 | 2025 | Breztri |
| Exact Sciences Corporation | $34.45 | 2023-2024 | Cologuard Collection Kit |
| Radius Health, INC. | $24.02 | 2023 | Tymlos |
| Neurocrine Biosciences, INC. | $23.80 | 2024 | Ingrezza |
| C. R. Bard, INC. & Subsidiaries | $23.78 | 2022 | |
| Medtronic, INC. | $21.99 | 2022 | |
| Becton, Dickinson and Company | $21.64 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.02 | 2021 | |
| Indivior INC. | $19.80 | 2025 | Sublocade |
| Hologic Sales and Service, LLC | $19.60 | 2024 | Thinprep 2000 Processor |
| Organon LLC | $19.56 | 2025 | Nexplanon |
| Seqirus USA INC | $19.48 | 2022 | |
| Shield Therapeutics INC | $18.26 | 2024 | |
| Astellas Pharma US INC | $17.93 | 2021 | |
| Daiichi Sankyo INC. | $16.79 | 2021 | |
| Boston Scientific Corporation | $15.88 | 2024 | Wavewriter Alpha Prime 16 |
| Acella Pharmaceuticals, LLC | $14.73 | 2023 | NP Thyroid 60 |
| Kowa Pharmaceuticals America, INC. | $14.23 | 2025 | Zoryve |
| Lucid Diagnostics INC. | $12.33 | 2022 | |
| Genentech USA, INC. | $5.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.